Stonehage Fleming Financial Services Holdings Ltd Makes New Investment in Edwards Lifesciences Corporation $EW

Key Points

• Stonehage Fleming Financial Services Holdings Ltd has invested approximately $1.34 million in Edwards Lifesciences Corporation, acquiring 17,080 shares during the 2nd quarter.
• Multiple institutional investors have also shown interest, with 79.46% of Edwards’ stock owned by such entities, highlighting increasing confidence in the medical research company.
• Analysts have raised their price targets for Edwards Lifesciences, with Piper Sandler setting a new target of $90, showing a positive outlook amidst recent earnings that exceeded expectations.

Stonehage Fleming Financial Services Holdings Ltd bought a new position in shares of Edwards Lifesciences Corporation (NYSE:EW - Free Report) during the 2nd quarter, according to its most recent disclosure with the SEC. The fund bought 17,080 shares of the medical research company's stock, valued at approximately $1,336,000.

Several other hedge funds and other institutional investors have also recently bought and sold shares of EW. Quantbot Technologies LP acquired a new position in shares of Edwards Lifesciences in the 1st quarter valued at about $26,000. SouthState Corp acquired a new position in shares of Edwards Lifesciences in the 1st quarter valued at about $27,000. Global X Japan Co. Ltd. lifted its stake in shares of Edwards Lifesciences by 116.1% in the 1st quarter. Global X Japan Co. Ltd. now owns 402 shares of the medical research company's stock valued at $29,000 after purchasing an additional 216 shares during the period. Tradewinds Capital Management LLC lifted its stake in shares of Edwards Lifesciences by 102.5% in the 1st quarter. Tradewinds Capital Management LLC now owns 405 shares of the medical research company's stock valued at $29,000 after purchasing an additional 205 shares during the period. Finally, Rossby Financial LCC acquired a new position in shares of Edwards Lifesciences in the 1st quarter valued at about $29,000. 79.46% of the stock is owned by institutional investors and hedge funds.

Insider Activity at Edwards Lifesciences

In other news, VP Daniel J. Lippis sold 4,114 shares of the company's stock in a transaction that occurred on Monday, July 28th. The stock was sold at an average price of $79.46, for a total value of $326,898.44. Following the completion of the transaction, the vice president directly owned 22,002 shares of the company's stock, valued at $1,748,278.92. This represents a 15.75% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, insider Larry L. Wood sold 8,950 shares of the company's stock in a transaction that occurred on Monday, August 18th. The shares were sold at an average price of $78.06, for a total value of $698,637.00. Following the completion of the transaction, the insider owned 206,900 shares in the company, valued at approximately $16,150,614. The trade was a 4.15% decrease in their position. The disclosure for this sale can be found here. Corporate insiders own 1.29% of the company's stock.

Wall Street Analyst Weigh In

EW has been the topic of a number of recent analyst reports. Piper Sandler boosted their price objective on Edwards Lifesciences from $83.00 to $90.00 and gave the company an "overweight" rating in a research note on Friday, July 25th. Royal Bank Of Canada boosted their target price on Edwards Lifesciences from $85.00 to $89.00 and gave the company an "outperform" rating in a research report on Friday, July 25th. Barclays boosted their target price on Edwards Lifesciences from $90.00 to $95.00 and gave the company an "overweight" rating in a research report on Friday, July 25th. Mizuho boosted their target price on Edwards Lifesciences from $87.00 to $95.00 and gave the company an "outperform" rating in a research report on Friday, July 25th. Finally, Weiss Ratings reaffirmed a "hold (c)" rating on shares of Edwards Lifesciences in a research report on Wednesday. Three investment analysts have rated the stock with a Strong Buy rating, twelve have assigned a Buy rating, nine have issued a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the company presently has an average rating of "Moderate Buy" and a consensus target price of $87.06.

Edwards Lifesciences Stock Performance

Shares of EW opened at $74.02 on Friday. The firm has a market capitalization of $43.46 billion, a P/E ratio of 10.65, a P/E/G ratio of 3.55 and a beta of 1.05. The company has a debt-to-equity ratio of 0.06, a quick ratio of 3.87 and a current ratio of 4.68. The stock has a 50 day moving average price of $78.09 and a two-hundred day moving average price of $76.13. Edwards Lifesciences Corporation has a 52 week low of $64.89 and a 52 week high of $83.00.

Edwards Lifesciences (NYSE:EW - Get Free Report) last released its earnings results on Thursday, July 24th. The medical research company reported $0.67 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.62 by $0.05. The company had revenue of $1.53 billion during the quarter, compared to analyst estimates of $1.49 billion. Edwards Lifesciences had a return on equity of 15.01% and a net margin of 72.96%.Edwards Lifesciences's quarterly revenue was up 11.9% on a year-over-year basis. During the same period in the prior year, the company posted $0.70 earnings per share. Edwards Lifesciences has set its Q3 2025 guidance at 0.540-0.60 EPS. FY 2025 guidance at 2.400-2.500 EPS. Equities analysts forecast that Edwards Lifesciences Corporation will post 2.45 earnings per share for the current fiscal year.

Edwards Lifesciences Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.

Want to see what other hedge funds are holding EW? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Edwards Lifesciences Corporation (NYSE:EW - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.